Tuesday, April 30, 2019

Glenmark launches cheaper SGLT2 inhibitor class of anti-diabetes drug in India

Glenmark launches cheaper SGLT2 inhibitor class of anti-diabetes drug in India The drug, generically called as Remogliflozin etabonate, is used in the treatment of type-2 diabetes mellitus in adults.

from Moneycontrol Business News http://bit.ly/2WilzOg

No comments:

Post a Comment

FII exodus deepens in 2026 at Rs 1.75 lakh crore as April outflows swell to Rs 43,967 crore; FOMC next trigger

Foreign institutional investors offloaded Indian equities worth Rs 17,140 crore last week, extending April's outflows to Rs 43,967 crore...